News
Otsuka receives vital Lupkynis MHRA authorisation
Otsuka has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised Lupkynis for use in combination with mycophenolate mofetil.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Otsuka has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised Lupkynis for use in combination with mycophenolate mofetil.